Glucocorticoids Promote Osteoclast Survival
Stopped early
Conditions studied: Osteoporosis
In brief
The purpose of this study is to determine the difference in response to bisphosphonate therapy in patients receiving excess glucocorticoids compared to patients with postmenopausal or male osteoporosis. Bisphosphonates are approved by the FDA for the treatment of postmenopausal women and osteoporotic men who are at high risk of fracture and in men and women with excess glucocorticoid administration.
Key facts
- Study ID
- NCT00572299
- Run by
- University of Arkansas
- People needed
- 3
- Starts
- 2004-01-01
- Expected to finish
- 2010-05-01
- Last updated by the study team
- 2011-08-30
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- 18 years old or greater
- agree to at least one bone biopsy
- agree to BMD, blood and urine tests
- receiving at least 10 mg/day of prednisone for at least three months
- either be a candidate for alendronate or be taking alendronate (70 mg/week for at least three months)
You may not qualify if…
- any metabolic bone disorder such as Paget's disease, renal osteodystrophy, parathyroid disease or osteomalacia
- obesity enough to make a biopsy difficult
- concurrent use of any tetracycline
- hypercalcemia
- kidney stones in the last two years
- home O2
- gastric surgery, stapling or bypass
- inflammatory bowel disease
- untreated thyroid disease
- organ transplants
- malabsorption
- anticoagulation
- current infection
- serious illness
- allergy to Demerol, Valium, iodine, tetracycline, tape
- use of anticonvulsant drugs, heparin, Forteo, calcitonin or high-dose fluoride within the past six months
Where it is running
- University of Arkansas hospitals and clinics and the Central Arkansas Veterans Healthcare System — Little Rock, Arkansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.